Tango Therapeutics (TNGX) Return on Capital Employed (2021 - 2026)
Tango Therapeutics' (TNGX) quarterly Return on Capital Employed came in at 29.17% in Q1 2026, up 2705.0% year-on-year from 1.04% in Q1 2025, and up 25.89% quarter-over-quarter from 39.36% in Q4 2025.
Tango Therapeutics (TNGX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Tango Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 29.17% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 2705.0% year-over-year to 29.17% in Q1 2026; TTM through Mar 2026 was 29.17%, a 2705.0% increase from a year earlier, with the FY2025 full-year figure at 33.13%, up 1218.0% from the prior year.
- Return on Capital Employed climbed to 29.17% in Q1 2026 per TNGX's latest filing, from 39.36% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 16.01% in Q1 2022 and bottomed at 72.79% in Q2 2025.
- The 5-year median for Return on Capital Employed is 33.74% (2023), against an average of 37.29%.
- Across the five-year window, Return on Capital Employed sank 3495 bps in 2025 and soared 2705 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 28.14% in 2022, then slipped by 10 bps to 30.9% in 2023, then sank by 59 bps to 49.14% in 2024, then gained by 20 bps to 39.36% in 2025, then rose by 26 bps to 29.17% in 2026.
- Per Business Quant, the three latest TNGX Return on Capital Employed figures stand at 29.17% (Q1 2026), 39.36% (Q4 2025), and 53.67% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Tango Therapeutics | 3.94 Bn | 3.78 Bn | - | -29.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.17% |
| Dec 31, 2025 | -39.36% |
| Sep 30, 2025 | -53.67% |
| Jun 30, 2025 | -72.79% |
| Mar 31, 2025 | -56.22% |
| Dec 31, 2024 | -49.14% |
| Sep 30, 2024 | -42.42% |
| Jun 30, 2024 | -37.85% |
| Mar 31, 2024 | -34.88% |
| Dec 31, 2023 | -30.90% |
| Sep 30, 2023 | -30.45% |
| Jun 30, 2023 | -33.74% |
| Mar 31, 2023 | -31.65% |
| Dec 31, 2022 | -28.14% |
| Sep 30, 2022 | -25.31% |
| Jun 30, 2022 | -22.19% |
| Mar 31, 2022 | -16.01% |
| Dec 31, 2021 | -12.26% |
| Sep 30, 2021 | -11.86% |
| Jun 30, 2021 | -26.01% |